CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 2,028 enrolled
Drug / intervention
flutamide +3 moredrug
Likely dose
Flutamide 250 mg orally three times daily beginning 2 months before RT and continuing until RT completion; Zoladex 3.6 mg subcutaneously monthly x4 or 3-month preparation; Lupron 7.5 mg intramuscularly monthly x4 or 3-month preparationAI-extracted
Key inclusion· 6
  • Histologically confirmed locally confined adenocarcinoma of the prostate, clinical stage T1b, T1c, T2a, or T2b
  • Negative lymph nodes (NX by imaging or N0 by surgical sampling)
  • Karnofsky performance status ≥70
  • PSA ≤20 ng/mL
Key exclusion· 7
  • Stage T1a or ≥T2c disease
  • Lymph node involvement (N1-N3)
  • Evidence of distant metastasis (M1)
  • PSA >20

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00002597
NCT00002597Phase 3Completed

A PHASE III TRIAL OF THE STUDY OF ENDOCRINE THERAPY USED AS A CYTOREDUCTIVE AND CYTOSTATIC AGENT PRIOR TO RADIATION THERAPY IN GOOD PROGNOSIS LOCALLY CONFINED ADENOCARCINOMA OF THE PROSTATE

Radiation Therapy Oncology Group·interventional·Posted Feb 27, 2004·Updated Jun 14, 2018

In Brief

A Phase 3 clinical trial evaluating flutamide, Zoladex, and 2 other interventions for Prostate Cancer. Completed, enrolled 2,028 participants across 239 sites in 2 countries.

Detailed Summary

RATIONALE: Radiation therapy (RT) uses high-energy x-rays to damage tumor cells. Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using flutamide, goserelin, and leuprolide may fight prostate cancer by reducing the production of androgens. It is not yet known which regimen of antiandrogen therapy is most effective for prostate cancer. PURPOSE: Randomized phase III trial to study the effectiveness of radiation therapy with or without antiandrogen therapy in treating patients who have stage I or stage II prostate cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesCanada, United States

Timeline

Phase 3CompletedFinished
1994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 27, 2004
Enrollment StartOct 1, 1994
Primary CompletionJul 1, 2011
Study CompletionMay 14, 2018
TodayJul 2, 2026
Enrollment to primary: 16.8 yearsPosted 22.3 years ago

Interventions

flutamidedrug

Two 125 mg capsules (t.i.d., p.o.) beginning two months before RT and continuing until RT is completed.

Zoladexdrug

3.6 mg s.c. monthly x 4 beginning two months before RT and continuing until RT is completed. The 3-month preparation may be used instead of three separate monthly injections.

Luprondrug

7.5 mg IM (intramuscular) monthly x 4 beginning two months before RT and continuing until RT is completed. The 3-month preparation may be used instead of three separate monthly injections.

radiation therapyradiation

46.8 Gy (1.8 Gy/day four to five times a week \[26 fx\]) to regional lymphatics followed by 19.8 Gy (1.8 Gy/day x 11 fx) for a total of 66.6 Gy to the prostate. Prostate only may be treated in defined circumstances.